New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment

xlomafota13 shared this article with you from Inoreader New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment Via Association française pour l'étude du cancer Bull Cancer. 2022 Jan 18:S0007-4551(21)00686-X. doi: 10.1016/j.bulcan.2021.10.007. Online ahead of print. NO ABSTRACT PMID:35063182 | DOI:10.1016/j.bulcan.2021.10.007 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.